Short Duration Treatment of Non-severe Community Acquired Pneumonia
NCT01963442 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 310
Last updated 2017-08-14
Summary
To investigate the non inferiority of a short lasting antibiotic treatment (3 days) when compared to a long lasting antibiotic treatment (8 days), at Day 15 after the beginning of treatment in terms of clinical efficacy, in adults admitted to emergency services for a non severe Community Acquired Pneumonia (PAC), who responded well to 3 days of beta-lactamin treatment (3GC or A/AC).
Conditions
- Community Acquired Pneumonia
Interventions
- RADIATION
-
Chest X-ray
at Day 0, Day 30 and relapse
- BIOLOGICAL
-
blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry
- DRUG
-
Augmentin
2 tablets 3 times a day for 5 days from Day 3
- DRUG
-
Placebo (for Augmentin)
2 tablets 3 times a day for 5 days from Day 3
- DRUG
-
Beta-Lactams
administered from Day 0 to Day 3
Sponsors & Collaborators
-
Versailles Hospital
lead OTHER
Principal Investigators
-
Anne-Claude CREMIEUX, Pr · Central Hospital Raymon Poincaré
-
Marie Christine DOMBRET, Dr · CHU Bichat
-
Matthieu GROH, Dr · CHU Cochin
-
Elizabeth ROUVEIX, Pr · CHU Ambroise Paré
-
Pascale LONGUET, Dr · CH Argenteuil
-
Daniel BENHAMOU, Dr · CHU Rouen
-
Sylvain DIAMANTIS, Dr · Melun Hospital
-
Jean-Emmanuel Kahn, Dr · Foch Hospital
-
Jean-François BOITIAUX, Dr · Pontoise Hospital
-
Jean-Pierre BEDOS, Pr · Central Hospital of Versailles
-
Jêrome PACANOWSKI, Dr · CHU Saint Antoine (Paris)
-
Valérie GARRAIT, Dr · CHI CRETEIL
-
Elena FOIS, Dr · CH Saint Denis
-
Benjamin WYPLOSZ, Pr · CH Bicêtre
-
Véronique DELCEY, Dr · CH Lariboisière
-
Gilles PIALOUX, Dr · CH Tenon
-
Matthieu REVEST, Dr · CHU Rennes Pontchaillou
-
Jean Paul STAHL, Dr · University Hospital, Grenoble
-
Virginie VITRAT, Dr · CH Annecy Genevois
-
Victoire De Lastours, Dr · CH Beaujon
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-11-30
- Primary Completion
- 2018-06-30
- Completion
- 2018-06-30
Countries
- France
Study Locations
More Related Trials
-
Comparison Between Amoxycillin/Clavulanic Acid and Oxacillin/Ceftriaxone for Community Acquired-pneumonia
NCT01166932 ·Status: COMPLETED ·Phase: PHASE4
-
Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia
NCT03452826 ·Status: COMPLETED ·Phase: NA
-
Duration of Antibiotic Therapy in Community - Acquired Pneumonia
NCT01492387 ·Status: UNKNOWN ·Phase: PHASE4
-
Duration of Antibiotic Treatment for Early VAP (DATE) Trial
NCT01994980 ·Status: COMPLETED ·Phase: NA
-
Duration of Antibiotic Treatment in Community-acquired Pneumonia
NCT05762328 ·Status: RECRUITING ·Phase: NA
-
Treatment's Duration of Acute Uncomplicated Pyelonephritis
NCT00873626 ·Status: COMPLETED ·Phase: PHASE4
-
Description of Pneumococcal Pneumonia
NCT03322670 ·Status: COMPLETED
-
Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia
NCT00887276 ·Status: TERMINATED ·Phase: PHASE4
-
Procalcitonin Guided Antibiotic Use in Acute Respiratory Tract Infections (PARTI)-Study
NCT00099840 ·Status: COMPLETED ·Phase: NA
-
Short Versus Long Antibiotic Course for Pleural Infection Management (SLIM Trial)
NCT04615286 ·Status: COMPLETED ·Phase: NA
-
Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia
NCT00270517 ·Status: UNKNOWN ·Phase: PHASE2
-
Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia
NCT04334850 ·Status: COMPLETED ·Phase: NA
-
Comparison of Two Antibiotic Regimens for the Treatment of Early Airways Infection With PA in Adults With Bronchiectasis
NCT06368804 ·Status: RECRUITING ·Phase: PHASE2
-
Trial on a Strategy Combining Rapid Diagnostic Testing and Antimicrobial Stewardship to Improve Antibiotic Use in Patients With Hospital-acquired Pneumonia.
NCT04153682 ·Status: COMPLETED ·Phase: NA
-
Study of Risk Factors for Developing Inhalation Pneumonia After Inhalation
NCT03108430 ·Status: UNKNOWN
-
Study on Costs and Safety of Early Conversion From Intravenous to Oral Antibiotic Treatment in Patients With Severe Community-Acquired Pneumonia
NCT00273676 ·Status: COMPLETED ·Phase: PHASE4
-
Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia.
NCT01683487 ·Status: COMPLETED
-
Application of the Recommendations of the SPLIF (French Society of Infectious Pathology) in a Geriatric Population on the Duration of Treatment for Bacterial Pneumonia
NCT06307730 ·Status: COMPLETED
-
Improving Antibiotic Use in Acute Care Treatment
NCT00144040 ·Status: COMPLETED ·Phase: NA
-
Community-Acquired Pneumonia : Evaluation of Corticosteroids
NCT02517489 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP
NCT01420744 ·Status: COMPLETED ·Phase: PHASE2
-
Impact of a Regional Antimicrobial Stewardship on the Length of Stay of Patients Admitted to Hospital With Pneumonia
NCT02276092 ·Status: COMPLETED
-
Microbiology and Clinical Outcome of Pneumonia
NCT00873522 ·Status: UNKNOWN
-
Multicenter Prospective Evaluation of the Incidence and Serotyes of Invasive Pneumoccocal Disease (IPD) Among Children Below 5 Years
NCT00843895 ·Status: UNKNOWN ·Phase: NA
-
Definition of Sub-phenotypes of Pneumonia Based on the Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures
NCT06916481 ·Status: RECRUITING